Nexomic Announces Multi-Year Collaboration with Burjeel Cancer Institute. Burjeel Cancer Institute has built a strong regional legacy as one of the UAE's leading oncology institutions, delivering comprehensive, multidisciplinary cancer care from diagnosis through treatment, survivorship, and palliative care. Based at Burjeel Medical City in Abu Dhabi, the institute is part of a JCI-accredited quaternary care hospital with more than 350 beds and over 60 medical specialties. BCI's scale reflects its clinical impact: it serves more than 5,000 oncology patients annually, conducts more than 10,000 screenings, and performs over 10,000 radiotherapy sessions each year. This volume, combined with its international accreditations and global collaborations, positions BCI as a major force in advancing cancer care across the UAE and the wider region.

Today, Nexomic enters a multi-year collaboration with Burjeel Cancer Institute to advance AI-derived biomarkers for precision oncology. Together, we aim to bring AI-derived biomarkers and clinically meaningful tumor biology insights closer to patients and oncologists deeper understanding of treatment response, and more personalized cancer care.

Nexomic is a precision-oncology AI company headquartered in Dublin, Ireland, decoding the heterogeneity and resistance in cancer through multi-omic foundation models to develop AI-derived biomarkers for oncology.

Biology, AI-Decoded.